Several anti-IL-17A inhibitors have been shown in vitro and in vivo to reduce the release of innate immune effectors and are currently being investigated in clinical trials for the treatment of several inflammatory conditions such as rheumatoid arthritis, uveitis, and psoriasis (22, –, 24). This evidence concerns the gene IL17A and rheumatoid arthritis.